Amgen Inc. Stock (US0311621009): Reports Strong Q1 2026 Results with Revenue Beat

Amgen Inc. released first-quarter 2026 results on April 29, beating revenue expectations with $8.3 billion, up 12% year-over-year, driven by blockbuster drugs like Enbrel and Prolia. The biotech giant reaffirmed its full-year guidance amid U.S. market strength.

Amgen Inc. on April 29, 2026, reported first-quarter results that exceeded Wall Street forecasts, posting revenue of $8.3 billion, a 12% increase from Q1 2025, according to the company release dated 04/29/2026. Adjusted EPS came in at $5.15, topping consensus estimates by 8 cents. U.S. sales, representing over 70% of total revenue, surged due to demand for inflammation and oncology treatments.

As of: April 30, 2026

By the AD HOC NEWS Editorial Team – Equity desk for biotech stocks.

At a glance

• Name: Amgen Inc.
• ISIN: US0311621009
• Sector/Industry: Biotechnology
• Headquarters/Country: Thousand Oaks, California, USA
• Key markets: U.S., Europe, Japan
• Main revenue drivers: Enbrel, Prolia, Repatha
• Primary exchange/trading venue: Nasdaq
• Trading currency: USD
• CEO: Robert A. Bradway, since 2012
• Latest quarterly results: Q1 2026 revenue $8.3B, published 04/29/2026
• Dividend: $2.25 per share quarterly, ex-date 04/16/2026

Amgen's business model in brief

Amgen Inc. develops and markets human therapeutics focused on inflammation, oncology, bone health, cardiovascular disease, and neuroscience. The company leverages biotechnology to create protein-based drugs, with a portfolio anchored by long-acting biologics. Peers like AbbVie and Regeneron also target similar therapeutic areas through biologic innovation.

Key revenue and product drivers for Amgen

Enbrel generated $1.2 billion in Q1 2026, up 5% year-over-year, per the company release dated 04/29/2026. Prolia sales hit $1.1 billion, boosted by osteoporosis awareness campaigns in the U.S. The company reaffirmed 2026 revenue guidance of $33-34 billion and adjusted EPS of $20.00-$21.50.

Industry trends and competitive position

The biotech sector faces patent cliffs but benefits from obesity and inflammation drug demand. Amgen's rare disease focus differentiates it, with U.S. Medicare coverage supporting volume growth.

Why Amgen matters for U.S. investors

Listed on Nasdaq under AMGN, Amgen trades in USD with significant U.S. revenue exposure from Medicare-reimbursed drugs. SEC filings provide transparency, and its inclusion in S&P 500 and biotech ETFs offers portfolio access.

Which type of investor may follow Amgen stock — and who may not?

Income-focused investors may track its reliable dividend growth, while growth seekers eye pipeline expansions. High-beta volatility may deter conservative fixed-income allocators.

What analysts are saying about Amgen stock

RBC Capital maintained Outperform with a $350 price target on 04/30/2026, citing pipeline momentum, per Reuters on 04/30/2026. JPMorgan raised its target to $340 from $320 on 04/29/2026 post-earnings.

Risks and open questions for Amgen

Patent expirations on key drugs like Enbrel by 2029 pose revenue risks, though biosimilars competition is mitigated by manufacturing barriers. Regulatory hurdles for new obesity candidates remain.

What investors may watch next

Amgen's Q2 earnings are scheduled for July 29, 2026, before market open, with a conference call at 8:00 a.m. ET.

Upcoming watch points

• Q2 2026: Earnings release July 29, conference 8:00 a.m. ET

Bottom line

Amgen's Q1 2026 beat underscores resilient demand for its core products amid U.S. healthcare spending. Investors monitor pipeline progress and dividend continuity as the company navigates biotech headwinds.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.